Routine CFO succession with no red flags — monitor for any future equity grant details or changes in financial reporting cadence, but no immediate trading catalyst.
Price Chart
Executive Summary
Apimeds Pharmaceuticals US, Inc. disclosed the resignation of Interim CFO Erick Frim effective September 29, 2026, and the appointment of Eric Sherb as CFO effective October 1, 2026. Sherb, a CPA with 18 years of experience, will receive a base salary of $60,000 per year. The resignation was not due to any disagreement with the company, and a replacement was named immediately, making this a routine executive transition.
Key Facts
- Interim CFO Erick Frim resigned effective September 29, 2026, with no disagreement with the company.
- Eric Sherb appointed as CFO effective October 1, 2026; he is a CPA with 18 years of capital markets experience.
- Sherb's base salary is $60,000 per year under an Executive Employment Agreement.
- Sherb had been serving as fractional CFO of a wholly owned subsidiary since February 2026; that engagement terminates upon his appointment.
Financial Impact
No material financial impact; CFO transition with immediate replacement at a modest base salary of $60,000/year.
Risk Factors
- Potential disruption from another CFO change within six months (prior interim CFO reappointed March 2026).
- Low base salary may indicate part-time or fractional arrangement, raising questions about executive commitment.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-105484 |
| Document: 0001213900-26-105484-index-headers.html | 0001213900-26-105484 |
| Document: 0001213900-26-105484-index.html | 0001213900-26-105484 |
| Document: 0001213900-26-105484.txt | 0001213900-26-105484 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | — | $3.05 (−25.61%) |
Sep 22, 2026 5w ago | 8-K | $2.29 | awaiting T+60 | — | $3.05 (+33.19%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $3.05 (−35.79%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $3.05 (−27.90%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $3.05 (−89.83%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $3.05 (−62.23%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $3.05 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers